Allos Therapeutics, Inc. Release: Four Pralatrexate (PDX) Studies to Be Presented at the 50th Annual Meeting of the American Society of Hematology

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that four abstracts describing results from pralatrexate (PDX) studies have been accepted for presentation at the 50th Annual Meeting of the American Society of Hematology (ASH), to be held December 6 - 9, 2008, in San Francisco, California.

Back to news